Project Grant HT94252310255
Award Date
4/1/23
Completion Date
3/31/27
Dollars Obligated
$2.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award for $1,383,874.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding research at the University of Maryland, Baltimore (UMB) to decipher the intramolecular regulatory mechanism of polycystin 1, a protein implicated in polycystic kidney disease. The award began on March 1, 2025 and is scheduled for completion on February 28, 2029. As a prominent public research university, UMB has...
Yale University was awarded an $11,577,868 project grant from the Defense Health Agency to research polycystic kidney disease under the Military Medical Research and Development program (CFDA 12.420). The grant period runs from September 1, 2021 through August 31, 2025. Through this funding, Yale researchers will investigate polycystic kidney disease as a disorder of glomerulotubular synchronization. The Military Medical Research and Development program aims to transform military and public...
This $309,528 Project Grant was awarded by the Defense Health Agency on February 1, 2024 under the Military Medical Research and Development program (CFDA 12.420) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI). The grant supports a project titled "Evaluating the Role of Somatic Mutations in Autosomal Dominant Polycystic Kidney Disease Using Single-Cell Genomics", which aims to advance scientific understanding and treatment of this condition through...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $1,640,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "Therapeutic Parameters and Mechanism of Action of Anti-miR-17 Drugs in ADPKD", will fund research to investigate novel therapeutic approaches for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The research seeks to...
The Department of the Army Medical Command awarded Yale University a $2,639,485 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from December 2021 through November 2025 to investigate inhibition of the IRE1alpha-XBP1 pathway using toyocamycin as a novel approach to inhibit progression of autosomal dominant polycystic kidney and liver disease. The Military Medical Research and Development program supports basic, applied, and...
This $309,928 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate ferritin as a biomarker for progression of autosomal polycystic kidney disease. The 2-year project, which began on February 1, 2024, aims to advance scientific knowledge and develop innovative therapies in this area of kidney disease. KUMCRI, a...
The Department of the Army Medical Command awarded an $8.686 million project grant to Ospedale San Raffaele S.R.L. of Italy to support the development of 2-deoxy-D-glucose for the treatment of polycystic kidney disease from July 1, 2022 to June 30, 2026. This grant is being funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...
This federal Project Grant award of $2,029,830.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to advance the understanding of polycystic kidney disease (PKD) proteins. The primary goals are to: 1) determine the structures and properties of the PKD1/PKD2, PKD1L1/PKD2, and PKDREJ/PKD2L2 protein complexes, which are critical for sensing mechanical and chemical...
Yale University received a $1,618,571 project grant award from the Defense Health Agency through the Military Medical Research and Development federal grant program (CFDA 12.420). The award will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...